(152) Harnessing cannabidiol and lipid nanocapsules to modulate P-glycoprotein in glioma

Introduction: Glioblastoma, the most common and aggressive brain tumor, has a median survival of 12-15 months with the therapy [1]. A major challenge in glioblastoma is the overexpression of P-glycoprotein (P-gP/ABCB1), an efflux transporter present in glioma cells, which plays a key role in multidrug resistance (MDR). Cannabidiol (CBD), has shown to inhibit P-gp activity in various types of cancer [2]. Analogously, lipid nanocapsules (LNCs) have also been reported to inhibit P-gp in distinct cancer types [3]. In this context, their effect on P-gp function and expression in glioblastoma are explored.